ZBIO (Zenas BioPharma) Additional Paid-In Capital : $705.14 Mil(As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Additional Paid-In Capital?

Zenas BioPharma's quarterly additional paid-in capital increased from Sep. 2024 ($694.16 Mil) to Dec. 2024 ($699.65 Mil) and increased from Dec. 2024 ($699.65 Mil) to Mar. 2025 ($705.14 Mil).

Zenas BioPharma's annual additional paid-in capital increased from Dec. 2022 ($1.03 Mil) to Dec. 2023 ($4.65 Mil) and increased from Dec. 2023 ($4.65 Mil) to Dec. 2024 ($699.65 Mil).

Zenas BioPharma Additional Paid-In Capital Historical Data

The historical data trend for Zenas BioPharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Additional Paid-In Capital Chart

Zenas BioPharma Annual Data

Trend

Dec22

Dec23

Dec24

Additional Paid-In Capital

1.03

4.65

699.65

Zenas BioPharma Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial					5.63	7.29	694.16	699.65	705.14

Zenas BioPharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Zenas BioPharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenas BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

852 Winter Street, Suite 250, Waltham, MA, USA, 02451

Website

https://www.zenasbio.com

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.